UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 25, 2013
Progenics Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|||
|
777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
||
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
||
Registrant's telephone number, including area code: (914) 789-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01
|
Other Events.
|
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today completed its previously-announced underwritten public offering of 8,500,000 primary shares of common stock at a public offering price of $4.40 per share. Net proceeds to Progenics were approximately $34.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. In the offering, Jefferies LLC acted as sole book-running manager and as representative of several underwriters named in the Underwriting Agreement entered into with the Company on June 20, 2013. The offering utilized a portion of the Company's $100 million shelf registration statement, including a June 20, 2013 prospectus supplement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|||
|
|
PROGENICS PHARMACEUTICALS, INC.
|
|||||
|
|
|
|
||||
|
|
By:
|
|
/s/ ANGELO W. LOVALLO, JR.
|
|||
|
|
|
|
Angelo W. Lovallo, Jr.
|
|||
|
|
|
|
Vice President, Finance & Treasurer
|
|||
|
|
|
|
(Principal Financial and Accounting Officer)
|
|||
Date: June 25, 2013